Abstract
Aim:
The cytotoxic activities of a series of bis-aziridinylnaphthoquinone, AZ1 to AZ4, on human lung carcinoma cell lines, H460, and normal lung cells fibroblast cell line, MRC-5, and the mechanisms of H460 cells induced by AZ4 were investigated.
Methods:
The MTT assay was used to determine the cell proliferation. Cell cycle was analysed by FACS. The activity of caspase 3, 8 and 9 was determined by cell-permeable fluorogenic detection system. Western blot assay was used to evaluate the regulation of cyclin B, Cdc-2, p53, p21, and the Bcl-2 protein.
Results:
AZ1 to AZ4 displayed various cytotoxicity activities against H460 and MRC-5 cells. Compared to those compounds, AZ4 was with the most effective agent among the 5 tested analogues at reducing H460 cell viability with an IC50 value of 1.23 μmol/L; it also exhibited weak cytotoxicity against MRC-5 cells with an IC50 value of 12.7 μmol/L. The results show that growth arrest on the G2-M phase of H460 cells induced by AZ4 for 24 h was discovered, and this might be altered with the reduced Cdc-2 protein expression of 47% at 2.0 μmol/L AZ4, but not with cyclin B protein expression. The AZ4 treated cells were then led to apoptosis after 48 h. This was associated with the activation of apoptotic enzyme caspase 3 and mediated by caspase 8, but not caspase 9 at various concentrations of AZ4 after being cultured for 48 h and 30 h, respectively. The anti-apoptotic protein (Bcl-2) expression in H460 cells altered by 39% with downregulation, and the p53 protein by 25% with upregulation after being cultured with 2.0 μmol/L AZ4 for 48 h. In a time-dependent wanrer, the expression of the p53 and p21 proteins were increased to the maximum at 24 h, and then decreased at 48.
Conclusion:
AZ4 represents a novel antitumor aziridinylnaphthoquinone with therapeutic potential against the non-small cell lung cancer cells.
Similar content being viewed by others
Article PDF
References
Pakunlu, RI, Wang, Y, Tsao, W, Pozharov, V, Cook, TJ, Minko, T, Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and anti-apoptic cellular defense: novel multicomponent delivery system. Cancer Res 2004; 64: 6214–24.
Brown, JM, Tumor microenvironment and the response to anti-cancer therapy. Cancer Biol Ther 2002; 1: 453–8.
Shannon, AM, Bouchier-Hayes, DJ, Condron, CM, Toomey, D, Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003; 29: 297–307.
Naylor, MA, Thomson, P, Recent advances in bioreductive drug targeting. Mini-Rev Med Chem 2001; 1: 17–29.
Phillips, RM, Burger, AM, Loadman, PM, Jarrett, CM, Swaine, DJ, Fiebig, HH, Predicting tumor responses to mitomycine C on the basis of DT-diaphorase activity or drug metabolism by tumorhomogenares: implications for enzyme-directed bioreductive drug development. Cancer Res 2000; 60: 6384–90.
Kim, JY, Kim, CH, Stratford, IJ, Patterson, AV, Hendry, JH, The bioreductive agents RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line. Int J Rad Oncol Biol Phys 2004; 58: 376–58.
Siim, BG, Pruijn, FB, Sturman, JR, Hogg, A, Hay, MP, Brown, JM, et al. Selective potentiation of hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR4317. Cancer Res 2004; 62: 736–42.
Lin, PS, Ho, KC, Yang, SJ, Tirapazamine (SR4233) interrupts cell cycle progression and induces apoptosis. Cancer Lett 1996; 105: 249–55.
Lee, AE, Wilson, WR, Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol App Pharmacol 2000; 163: 50–9.
Smitskamp-Wilms, E, Giaccone, G, Pinedo, HM, Laan, BFAM, Peters, GJ, DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 1995; 72: 917–21.
Danson, S, Ward, TH, Butler, J, Ranson, M, DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev 2004; 30: 437–49.
Workman, P, Walton, MI, Enzyme directed bioreductive drug development. In: Fielden, EM, Wardman, P, editors, Selective activation of drug by redox processes. New York: Plenum Press; 1990. p 173–91.
Huang, ST, Kuo, HS, Lin, CM, Tsai, HD, Peng, YC, Chen, CT, et al. Synthesis and biological evaluation of novel bis-aziridinylnaphthoquinone derivatives. Oncology Res 2003; 11: 199–204.
Skehan, P, Storeng, R, Scudiero, D, Monks, A, McMahon, J, Vistica, D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107–12.
Komoriya, A, Packard, BZ, Brown, MJ, Wu, ML, Henkar, PA, Assessment of caspase activities in intact apoptotic thymocytes using cell-permeable fluorogenic caspase substrates. J Exp Med 2000; 191: 1819–28.
Bacus, SS, Gudkov, AV, Lowe, M, Lyass, L, Yung, Y, Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogen 2001; 20: 147–55.
Dive, C, Gregory, CD, Phipps, DJ, Evans, DL, Miliner, AE, Wyllic, AL, Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim Biophys Acta 1992; 1133: 275–81.
Scheer, M, Kuebler, AC, Zoller, JE, Chemoprevention of oral squamous cell carcinomas. Onkologie 2004; 27: 187–93.
Hsu, S, Singh, B, Schuster, G, Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. Oral Oncol 2004; 40: 461–73.
Koontongkaew, S, Chareonkitkajorn, L, Chanvitan, A, Leelakriangsak, M, Amornphimolttham, P, Alteration of p53, pRb, cyclin D (1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol 2000; 36: 334–9.
Schmitt, CA, Low, SW, Apoptosis and therapy. J Pathol 1999; 197: 127–37.
Evans, GL, Vousden, KH, Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–8.
Pirollo, KF, Bouker, KB, Chang, EH, Does p53 status influence tumor response to anticancer therapies? Anti-cancer Drugs 2000; 11: 419–32.
Nylader, K, Dabelsteen, E, Hall, PA, The p53 molecular and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2000; 29: 413–25.
Kaul, R, Mukherjee, S, Ahmed, F, Bhat, MK, Chhipa, R, Galande, S, et al. Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice. Int J Cancer 2003; 103: 606–15.
Gartel, AL, Feliciano, IL, Tyner, A, A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res 2003; 13: 405–8.
Nikitakis, NG, Sauk, JJ, Papanicolaou, SI, The role of apoptosis in oral disease: Mechanisms; aberrations in neoplastic, autoimmune, infectious, hematologic, and developmental diseases; and therapeutic opportunities. Oral Surg Oral Med Oral Pathol Oral Radiol & Endodo 2004; 97: 476–90.
Gibson, LF, Fortney, J, Magro, G, Ericoson, SG, Lynch, JP, Landreth, KS, Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. Breast Cancer Res Treat 1999; 55: 107–17.
Yamamoto, K, Ichijo, H, Korsmeyer, SJ, BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 1999; 19: 8469–78.
Karl, A, Nath, KA, Provenance of the protective property of p21. Am J Physiol Renal Physiol 2005; 289: F512–3.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Shin-Kong Wu Ho-Su Memorial Hospital (No SKH-FJU-92–03).
Rights and permissions
About this article
Cite this article
Shyu, Kg., Huang, St., Kuo, Hs. et al. Antitumor activity of a novel bis-aziridinylnaphthoquinone (AZ4) mediating cell cycle arrest and apoptosis in non-small cell lung cancer cell line NCI-H460. Acta Pharmacol Sin 28, 559–566 (2007). https://doi.org/10.1111/j.1745-7254.2007.00508.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00508.x
Keywords
This article is cited by
-
Antitumorigenic effect of atmospheric-pressure dielectric barrier discharge on human colorectal cancer cells via regulation of Sp1 transcription factor
Scientific Reports (2017)
-
Preferential killing of human lung cancer cell lines with mitochondrial dysfunction by nonthermal dielectric barrier discharge plasma
Cell Death & Disease (2013)